Recruiting

HRS-PHip Replacement System (HRS-P) in Primary Total Hip Arthroplasty

Sponsor:

Hip Innovation Technology

Code:

NCT02836262

Conditions

Osteoarthritis of Hip

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Interventions

HIT Hip Replacement System

Study Details

Brief summary:

To evaluate effectiveness and safety of HHRS in subjects undergoing total hip arthroplasty (THA). Effectiveness will be evaluated using patient-reported, clinical, radiologic, and radiostereometric outcomes. Safety will be evaluated through the collection of device-related and unanticipated device-related adverse events.

Conditions

Osteoarthritis of Hip

Study ID

NCT02836262

Start date

Aug 25, 2017

Status verified date

Sep, 2026

Completion date

Sep 16, 2032

Anticipated

Primary completion date

Sep 16, 2029

Anticipated

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Patient has a non-inflammatory degenerative joint disease (NIDJD) or any of its composite diagnoses such as osteoarthritis, avascular necrosis, traumatic arthritis, slipped capital epiphysis, fracture of the pelvis, and diastrophic variant requiring unilateral primary total hip replacement.
Age between 65 and 79 years (inclusive) at the time of enrollment.
Patient is a suitable candidate for primary total hip replacement at the discretion of the Investigator.
Pre-surgery (within 28 days before surgery) WOMAC Global Score of 40 or larger on a scale from 0 (best) to 96 (worst)
Signed and dated informed consent document.
Patient is willing and able to participate in required follow-up visits at the Investigational site and to complete study procedures and questionnaires.

Exclusion Criteria:

Patient has had total hip replacement, hemi-arthroplasty, or fusion in either hip in the last 12 months;
Patient has planned total hip arthroplasty on a contra-lateral joint in the next 12 months;
Patient has a known allergy to any component of the study device;
Patient has a history of active sepsis in the joint;
Patient has an insufficient acetabular or femoral bone stock in which good anchorage of the implants are unlikely or impossible;
Patient has total or partial absence of the muscular or ligamentous apparatus;
Patient has known moderate to severe renal insufficiency;
Patient has vascular insufficiency, muscular atrophy, or neuromuscular disease in either leg (based on the Investigator's discretion);
Patient has a deformity of the affected limb or significant anatomic variance of the affected hip;
Patient has an active malignancy or history of invasive malignancy within the last five years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix definitively treated more than 1 year prior to enrollment may enter the study;
Patient has any condition which may, in the opinion of the Investigator, interfere with the total hip replacement survival or patient outcomes (e.g. Paget's disease, Charcot's disease);
Patient has rheumatoid arthritis or other autoimmune condition that affect joints (e.g. Lupus Arthritis);
Patient has any condition that would interfere with patient self-assessment or pain, the function or quality of life required for patient reported outcomes during the study (based on the Investigator's discretion);
Body Mass Index (BMI) of 40 or more;
Patient has an active infection (e.g. hepatitis, AIDS, ARC) - systemic or at the site of intended surgery;
Patient is currently participating in any investigational study not related to this study's pre-operative or post-operative care;
Patient has any other severe acute or chronic medical condition that may interfere with the interpretation of the study results, in the judgment of the Investigator, which would make the patient inappropriate for entry into this study;
Patient has a history of metabolic bone disease (e.g. Paget's disease or osteomalacia);
Patient is currently pregnant or is planning to become pregnant.

Study Design

Enrollment

100 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: HIT Hip Replacement System (HRS)

Single group assignment with historical controls.

Interventions

HIT Hip Replacement System

Primary outcome measure

Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) v3.0 Likert Scale Functional Limitations Score between baseline (pre-operative) and the 730- day post-operative follow-up time point. [ Time Frame: between pre-operative and 730 days (24 months) ]
Change in Harris Hip Score between baseline (pre-operative) and the 730-day post-operative follow-up time point. [ Time Frame: between pre-operative and 730 days (24 months) ]

Central Contacts and Locations

Central contacts

Linda Braddon, PhD

770-837-2681 LGB@SecureBME.com

Thomas Turgeon, MD

204-926-1218 tturgeon@cjrg.ca

Locations

Orthopaedic Innovation Centre

Recruiting

Winnipeg, Manitoba, Canada, R2K 2M9

Contacts

Thomas Turgeon, MD

(204) 926-1218 tturgeon@cjrg.ca

Sarah Tran

(204) 926-1231 stran@orthoinno.com

Principal Investigator:

Thomas Turgeon, MD

More Information

Sponsor

Hip Innovation Technology

Last update posted

Sep 21, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-23. This information was provided to ClinicalTrials.gov by Hip Innovation Technology on 2026-09-21. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.